Skin And Skin Structure Streptococcus Agalactiae Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for skin and skin structure streptococcus agalactiae infection. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
4
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Skin And Skin Structure Streptococcus Agalactiae Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating skin and skin structure streptococcus agalactiae infection. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
30
2
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Teflaro
CEFTAROLINE FOSAMIL
 AbbVie 4 61 — 2030-09-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8247400 Teflaro method of use 73 2031-02-10
8247400 Teflaro method of use 73 2031-02-10
9629861 Teflaro formulation 48 2030-09-21
9629861 Teflaro formulation 48 2030-09-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9629861 Teflaro formulation 48 2030-09-21
9629861 Teflaro formulation 48 2030-09-21
8247400 Teflaro method of use 73 2031-02-10
8247400 Teflaro method of use 73 2031-02-10

Related